Corbus Pharmaceuticals Holdings, Inc. (CRBP)
NASDAQ: CRBP · Real-Time Price · USD
9.82
-0.26 (-2.58%)
At close: Apr 28, 2026, 4:00 PM EDT
9.97
+0.15 (1.53%)
After-hours: Apr 28, 2026, 4:30 PM EDT
CRBP Employees
Corbus Pharmaceuticals Holdings had 36 employees as of December 31, 2025. The number of employees increased by 8 or 28.57% compared to the previous year.
Employees
36
Change (1Y)
8
Growth (1Y)
28.57%
Revenue / Employee
n/a
Profits / Employee
-$2,181,583
Market Cap
174.17M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 36 | 8 | 28.57% |
| Dec 31, 2024 | 28 | 9 | 47.37% |
| Dec 31, 2023 | 19 | -14 | -42.42% |
| Dec 31, 2022 | 33 | -8 | -19.51% |
| Dec 31, 2021 | 41 | -35 | -46.05% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Protalix BioTherapeutics | 226 |
| Humacyte | 184 |
| Tonix Pharmaceuticals Holding | 142 |
| Cartesian Therapeutics | 75 |
| Precision BioSciences | 68 |
| Acumen Pharmaceuticals | 61 |
| Korro Bio | 58 |
| Unicycive Therapeutics | 22 |
CRBP News
- 21 days ago - Corbus Offers Upside Despite Post-FDA Update, Analyst Highlights Competitive Edge - Benzinga
- 7 weeks ago - Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 2 months ago - Corbus Pharmaceuticals Holdings Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference - Transcripts
- 2 months ago - Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference - GlobeNewsWire
- 3 months ago - Corbus Pharmaceuticals Holdings Transcript: 44th Annual J.P. Morgan Healthcare Conference - Transcripts
- 4 months ago - Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 4 months ago - Corbus Pharmaceuticals Holdings Transcript: Study Update - Transcripts
- 4 months ago - Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss - GlobeNewsWire